What does Rallybio Corporation do?

Rallybio Corporation (RLYB) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is RLYB's market cap?

Rallybio Corporation (RLYB) has a market capitalization of approximately $89.7 million, as of July 21, 2026, based on the most recent share price and shares outstanding.

Does RLYB pay a dividend?

No — Rallybio Corporation (RLYB) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Rallybio Corporation (RLYB) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

RLYB

Rallybio Corporation

NASDAQ·Biotechnology · Healthcare

$16.91$0.20+1.20%

After hours·$16.91+0.00%

Market cap$89.74M·Market closed·Jul 21 8:00 PM UTC

Price Chart

$16.91+$0.20 (+1.20%)today

−85.01%CAGR −31.69%

Select date range

FromTo

Jul 29, 2021Jul 29, 2021 → Jul 22, 2026· 5.0 yrsJul 22, 2026

Key Metrics

RLYB does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)$3.92

P/E Ratio (FWD)4.31

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateAug 6

Last Report DateMay 13

Reported vs Estimate−$1.46 vs −$1.20

Earnings Surprise−21.7%

FinancialsFinancials Tab

Revenue$858.00K

Net Income−$7.82M

Net Margin−911.1%

Operating Cash Flow−$27.59M

Capital Expenditures$0.00

Free Cash Flow−$27.59M

Return on Equity−15.5%

Return on Invested Capital−9.4%

Net Cash$46.64M

Analyst Estimates

PRO

Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.

Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for RLYB and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how RLYB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RLYB and 80,000+ other tickers.

About Rallybio Corporation

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic…

CEO: Stephen Uden
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Employees: 9
Website: www.rallybio.com

Peers

Peers Tab

INTS

Intensity Therapeutics, Inc.

Cap

$8.3M

SONN

Sonnet BioTherapeutics Holdings, Inc.

Cap

$8.4M

ITRM

Iterum Therapeutics plc

Cap

$1.6M

Latest News

News Tab

Frequently Asked Questions About RLYB

What does Rallybio Corporation do?: Rallybio Corporation (RLYB) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is RLYB's market cap?: Rallybio Corporation (RLYB) has a market capitalization of approximately $89.7 million, as of July 21, 2026, based on the most recent share price and shares outstanding.
Does RLYB pay a dividend?: No — Rallybio Corporation (RLYB) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is RLYB profitable?: Rallybio Corporation (RLYB) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

Rallybio Corporation

Frequently Asked Questions About RLYB

Rallybio Corporation

Price Chart

Key Metrics

Analyst Estimates

Value Graph

Income Statement Flow

About Rallybio Corporation

Peers

Latest News

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Frequently Asked Questions About RLYB

Price Chart

Key Metrics

Analyst Estimates

Value Graph

Income Statement Flow

About Rallybio Corporation

Peers

Latest News

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB